Taken together, the existing evidence and our results suggest that an increase in serum AnxA1 concentration predicts the progression of CAP to SCAP and the need to initiate glucocorticoids, although additional studies are needed to confirm this possibility. The gene discussed is ANXA1; the disease is syringocystadenoma papilliferum.